Clinical Trial Update: Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6) [Phase 3]

View source ↗

Summary

The EDELWEISS 6 Phase 3 extension study evaluating linzagolix for endometriosis-associated pain has completed, with results posted on 2024-04-30.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometriosis

Drugs mentioned

• Linzagolix (linzagolix)

Snippet

Sponsor: Kissei Pharmaceutical Co., Ltd. | Conditions: Endometriosis | Phase 3 | Status: COMPLETED | Results posted: 2024-04-30